Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- Check6 days agoChange DetectedA new publication reference has been added to the Publications section, citing a 2026 Ther Adv Hematol article on ruxolitinib in GVHD. This addition expands the related literature linked to the REACH3 study page without modifying study details or eligibility.SummaryDifference0.0%

- Check13 days agoChange DetectedThe page's revision has been updated to v3.5.4, signaling a small maintenance or metadata update rather than a change to the study data.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows a revised tag 'Revision: v3.5.3', indicating an updated version of the page content. The previous revision tag 'v3.5.2' was replaced.SummaryDifference0.0%

- Check41 days agoChange DetectedThe page now displays an updated site revision marker (v3.5.2 instead of v3.5.0). This reflects a technical site/version update without changing the study information shown.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision history updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.0%

- Check84 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page header. This appears to be a minor version update and does not modify study details.SummaryDifference0.0%

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.